» Articles » PMID: 34615577

Clinical Standards for the Assessment, Management and Rehabilitation of Post-TB Lung Disease

Abstract

Increasing evidence suggests that post-TB lung disease (PTLD) causes significant morbidity and mortality. The aim of these clinical standards is to provide guidance on the assessment and management of PTLD and the implementation of pulmonary rehabilitation (PR). A panel of global experts in the field of TB care and PR was identified; 62 participated in a Delphi process. A 5-point Likert scale was used to score the initial ideas for standards and after several rounds of revision the document was approved (with 100% agreement). Five clinical standards were defined: Standard 1, to assess patients at the end of TB treatment for PTLD (with adaptation for children and specific settings/situations); Standard 2, to identify patients with PTLD for PR; Standard 3, tailoring the PR programme to patient needs and the local setting; Standard 4, to evaluate the effectiveness of PR; and Standard 5, to conduct education and counselling. Standard 6 addresses public health aspects of PTLD and outcomes due to PR. This is the first consensus-based set of Clinical Standards for PTLD. Our aim is to improve patient care and quality of life by guiding clinicians, programme managers and public health officers in planning and implementing adequate measures to assess and manage PTLD.

Citing Articles

Post-tuberculous bronchiectasis in adults: The never-ending story.

Gomez-Olivas J, Oscullo G, Martinez-Garcia M J Clin Tuberc Other Mycobact Dis. 2025; 38:100391.

PMID: 40007943 PMC: 11851110. DOI: 10.1016/j.jctube.2023.100391.


"You find yourself in a very humiliating situation": experiences of people living with post-tuberculosis lung disease in Brazil.

de Almeida C, Furin J, Sumiya A, Silva D, Mitnick C Front Public Health. 2025; 12():1431881.

PMID: 39776473 PMC: 11703962. DOI: 10.3389/fpubh.2024.1431881.


Silicotuberculosis: a critical narrative review.

Ehrlich R, Murray J, Said-Hartley Q, Rees D Eur Respir Rev. 2024; 33(174).

PMID: 39694587 PMC: 11668511. DOI: 10.1183/16000617.0168-2024.


TB survivors: why curing TB is sometimes not enough.

Pontali E, Centis R IJTLD Open. 2024; 1(12):531-532.

PMID: 39679207 PMC: 11636497. DOI: 10.5588/ijtldopen.24.0530.


Viewpoint on WHO implementation guidance on tuberculosis infection prevention and control.

Akkerman O, Migliori G, Falzon D, Garcia-Basteiro A, Kanchar A, Konstantynovska O Eur Respir J. 2024; 64(6).

PMID: 39542460 PMC: 11635381. DOI: 10.1183/13993003.00109-2024.


References
1.
Ranzani O, Rodrigues L, Bombarda S, Minto C, Waldman E, Carvalho C . Long-term survival and cause-specific mortality of patients newly diagnosed with tuberculosis in São Paulo state, Brazil, 2010-15: a population-based, longitudinal study. Lancet Infect Dis. 2019; 20(1):123-132. PMC: 6928568. DOI: 10.1016/S1473-3099(19)30518-3. View

2.
Nahid P, Mase S, Migliori G, Sotgiu G, Bothamley G, Brozek J . Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med. 2019; 200(10):e93-e142. PMC: 6857485. DOI: 10.1164/rccm.201909-1874ST. View

3.
Holland A, Spruit M, Troosters T, Puhan M, Pepin V, Saey D . An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014; 44(6):1428-46. DOI: 10.1183/09031936.00150314. View

4.
Gunther G, Ithete S . Clinical care for patients with post-TB lung disease. Int J Tuberc Lung Dis. 2021; 25(3):252-253. DOI: 10.5588/ijtld.20.0824. View

5.
Bongomin F . Post-tuberculosis chronic pulmonary aspergillosis: An emerging public health concern. PLoS Pathog. 2020; 16(8):e1008742. PMC: 7440622. DOI: 10.1371/journal.ppat.1008742. View